Sponsor intelligence · INDUSTRY
Clinical trials sponsored by
Novartis Pharmaceuticals.
Real, source-linked trial activity for Novartis Pharmaceuticals: 20 tracked trials, by phase and status, newest first. New trials = pipeline expansion = CRO, site, and reagent demand.
✔ Verified against the public NIH RePORTER & ClinicalTrials.gov records as of Sep 19, 2026. Source-linked, daily-refreshed.
N/A 8PHASE2 6PHASE3 3PHASE1 2PHASE4 1
Newest Novartis Pharmaceuticals trials
| Posted | Trial | Phase | Status | |
|---|---|---|---|---|
| 5d ago | A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Ger | N/A | ACTIVE_NOT_RECRUITING | ↗ |
| 9d ago | Investigation of a Remibrutinib- and Omalizumab-based Treatment Algori | Ph 3 | NOT_YET_RECRUITING | ↗ |
| 10d ago | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Ag | Ph 2 | COMPLETED | ↗ |
| 10d ago | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Ag | Ph 2 | RECRUITING | ↗ |
| 17d ago | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | Ph 1 | NOT_YET_RECRUITING | ↗ |
| 17d ago | A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in P | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 27d ago | A Drug-drug Interaction Study to Assess the Effect of Phenytoin and It | Ph 1 | NOT_YET_RECRUITING | ↗ |
| 31d ago | A Study to Assess the Efficacy and Safety of GIA632 Across a Range of | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 34d ago | A 52-week Study of Remibrutinib in IgE-mediated Food Allergy | Ph 3 | NOT_YET_RECRUITING | ↗ |
| 34d ago | A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Z | N/A | NOT_YET_RECRUITING | ↗ |
| 39d ago | A Real-World Study of Treatment Patterns, Tolerability and Effectivene | N/A | COMPLETED | ↗ |
| 40d ago | A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropat | N/A | COMPLETED | ↗ |
| 45d ago | A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS8 | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 48d ago | A Study of Treatment Patterns and Annualized Relapse Rate in Multiple | N/A | COMPLETED | ↗ |
| 51d ago | Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk P | Ph 3 | NOT_YET_RECRUITING | ↗ |
| 52d ago | A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients | N/A | NOT_YET_RECRUITING | ↗ |
| 52d ago | A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment | N/A | NOT_YET_RECRUITING | ↗ |
| 52d ago | A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 61d ago | A Study to Characterize the Clinical Presentation and Course of Crypto | N/A | RECRUITING | ↗ |
| 62d ago | Study to Assess Safety and Clinical Responses With Coartem® Baby Dispe | Ph 4 | NOT_YET_RECRUITING | ↗ |
Get this lane pushed to you the day a new grant or trial lands
Free email digest + a daily new-funding feed (JSON / MCP / webhook) of newly-awarded NIH grants and newly-registered clinical trials for Novartis Pharmaceuticals (trial sponsor). Watch institutions, PIs, sponsors, and topics. Newly-funded labs = new buyers, today.